Navigation Links
Roche Statement Regarding Tamiflu U.S. Label Revision
Date:3/4/2008

NUTLEY, N.J., March 4 /PRNewswire/ -- Roche has informed healthcare professionals that the prescribing information for Tamiflu (oseltamivir phosphate) has been updated to reflect recommendations made by the FDA Pediatric Advisory Committee at a November 27, 2007 meeting regarding neuropsychiatric events. The revision is an update to a label change made in November of 2006 and includes information that influenza itself has been associated with a variety of neuropsychiatric events and that these reports appear to be uncommon.

The changes to the label reflect observations from a growing body of data, which shows no evidence of a causal relationship between Tamiflu and the reported events. The data shows that these neuropsychiatric adverse events also occurred in flu patients who were not taking Tamiflu. In fact, emerging evidence suggests that influenza itself may cause neuropsychiatric adverse events. In addition to clinical trials conducted prior to the approval of Tamiflu by the FDA, extensive post-marketing studies have been conducted and additional research is underway by Roche, Chugai and the Japanese health authority.

Roche agrees that it is important that healthcare professionals and patients know that all children with flu should be monitored, regardless of whether they are taking an antiviral medication. If any sign of unusual behavior is observed, a healthcare professional should be contacted immediately.

Antivirals like Tamiflu play an important role in the prevention and treatment of influenza. Tamiflu has been used by more than 48 million people worldwide, including nearly 21 million children, since its approval in 1999. Tamiflu is approved for the treatment and prevention of influenza in patients over one year of age and is one of two antiviral medications recommended by the CDC for the 2007-2008 influenza season.

Roche is committed to ensuring safe and appropriate use of our medications and will continue to conduct appropriate post-marketing monitoring and research.

For full U.S. prescribing information, please visit http://www.tamiflu.com.


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem announces departure of two members of management team
2. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
3. Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
4. Roche Completes Tender Offer for Ventana Shares
5. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
6. Roche Purchases Shares in Tender Offer for Ventana
7. Mayo Clinic Seeks Mitigation for Rochester as Condition of Canadian Pacific - DM&E Railroad Merger
8. Roche Plans to Complete Ventana Offer on February 7th
9. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
10. Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008
11. Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in Worlds Poorest Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... ... May 19, 2017 , ... As a groundbreaking surgeon on ... importance of prostate cancer screenings. Early detection of the disease, he says, can make ... at Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate ...
(Date:5/19/2017)... ... 18, 2017 , ... CloSYS products which are marketed as the gentle giants ... mouth and gum health, which is linked to one’s overall health. Since 1991 when ... the powerful ways in which CloSYS products immediately helped eliminate bad breath as well ...
(Date:5/19/2017)... ... May 18, 2017 , ... Somnoware, a leading provider of ... physicians to independently dispense CPAP devices and supplies, such as machines, filters, tubing, and ... dispense the devices. Device registration for daily usage data is automated, and a DME ...
(Date:5/18/2017)... ... , ... Originally launched to market as the EPIK Learning Tab, the highly ... expansion of their product line, the company believed it was the right time to ... will be any tablet product sold by EPIK Learning. This year there will ...
(Date:5/18/2017)... ... May 18, 2017 , ... The nZone’s ... educational and charitable organization which sponsors numerous programs and activities aimed at supporting ... event over Memorial Day Weekend. , The MURPH Challenge, named after LT. ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... CSSi, the global leader in patient recruitment, ... is proud to announce the launch of its newly ... both enriched content and a customized layout that provides ... already well-established position as the top global patient recruitment ... months of hard work, we are delighted to officially ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke Awareness ... of the most important methods to prevent a stroke: ... Centers for Disease Control and Prevention, undetected and uncontrolled ... Omron, the global leader in personal heart health ... elimination of heart attack and stroke and is advancing ...
Breaking Medicine Technology: